Chronic Lymphocytic Leukemia increases the pool of peripheral blood hematopoietic stem cells and skews differentiation by Santoro, Antonella et al.
STIMULUS REPORT
Chronic lymphocytic leukemia increases the pool of peripheral blood
hematopoietic stem cells and skews differentiation
Antonella Santoro,1 Camelia Andrei,2 Clare Bryant,2 Emily Calderbank,1 Alison Wray,3 Joanna E. Baxter,3 Anna Godfrey,2 Elisa Laurenti,1,*
and Ingo Ringshausen1,*
1Department of Haematology andWellcome and MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom; 2Haematopathology & Oncology
Diagnostics Service, Department of Haematology Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; and 3Cambridge Blood and Stem Cell
Biobank, University of Cambridge, United Kingdom
Key Points
•CLL increases the pool








Chronic lymphocytic leukemia (CLL) is an indolent B-cell malignancy invariably infiltrating the bone
marrow. Although treatment options for patients with advanced disease have significantly improved in
the past years, the disease remains incurable, and after emergence of therapy, resistant disease patients
succumb to infections because of secondary bone marrow failure. The underlying mechanisms impairing
normal hematopoiesis in patients with CLL are poorly defined.
Mature, differentiated B cells, either pre- or postgerminal center, are considered the cell of origin of
unmutated and mutated CLL, respectively.1 However, this paradigm has been challenged based on the
observation of CLL-recurrent mutations present in a fraction of hematopoietic stem cells (HSCs),2 which
demonstrated a differentiation bias toward the lymphoid lineage in a xenotransplantation model.3 To
what extent this skewed differentiation of HSCs contributes to bone marrow failure of patients with
advanced disease remains unknown. Other mechanisms contributing to suppressed hematopoiesis in
CLL include the secretion of tumor necrosis factor-a by malignant B cells, which not only inhibits the
growth of HSCs in vitro4,5 but also has complex effects on HSCs and progenitor cell function in vivo,
including enhancing myelopoiesis. In support of this hypothesis, higher levels of plasma tumor necrosis
factor-a correlate with anemia in patients with CLL. In addition, as shown by us6 and others,7 “disease-
induced” activation of NF-kB in bone marrow stroma cells further contributes to an inflammatory
microenvironment and potentially aggravates bone marrow failure.
We hypothesized that the inflammatory microenvironment induced by bone marrow–infiltrating CLL cells
negatively affects normal hematopoiesis by skewing hematopoietic stem and progenitor cell (HSPC)
lineage commitments and residence in the bone marrow.
Methods
We assessed the frequency of HSPCs in the peripheral blood (PB) of 69 individual patients with the
diagnosis of CLL, and 21 age-matched healthy controls. All individuals consented to the use of PB
samples for research purposes and in accordance with the Declaration of Helsinki. These studies were
approved by the Cambridgeshire Research Ethics Committee (07/MRE05/44). PB samples were
collected in the afternoon, when circulation of hematopoietic progenitors is known to reach its peak
because of circadian oscillation.8 To assess the absolute numbers of CD341 cells, nonpurified
peripheral blood mononuclear cells from 5 mL PB were stained and gated for CD34 positivity and CD19
negativity to quantify the total amount of circulating hematopoietic progenitor cells, using precision
counting beads (Biolegend) and flow cytometry. Relative frequencies of HSPC subsets were assessed
on CD341-enriched cells using beads (Miltenyi Biotec) and following the gating strategy depicted in
supplemental Figures 1 and 2.
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Figure 1. Altered frequencies of PB HSPCs in patients with CLL. (A-C) Absolute numbers of global (CD341) hematopoietic progenitors from nonpurified peripheral
blood mononuclear cells isolated from PB. (A) Comparison between aged-matched controls (n 5 20) and patients with CLL (n 5 54) is shown. Unpaired Student t test. (B)
Quantification of CD341 cells in treatment-naive patients, separated by Binet stage (ordinary 1-way analysis of variance [ANOVA] followed by unpaired Student t tests). Binet
stage, A 5 25; B 5 11; C 5 4. (C) Abundance of CD341 progenitors in the CLL cohort by treatment type (ordinary 1-way ANOVA followed by unpaired Student t tests).
Controls, N 5 20; naive patients with CLL, n 5 40; ibrutinib-treated, n 5 3; previously treated, n 5 11. (D) Representative fluorescence-activated cell sorting plots of CMPs-
MEPs and ST-HSC abundance of freshly isolated CD341 cells. Values indicate abundance of the specific population, as relative frequency of total CD341 pool. (E) Dot-plot
showing relative abundance of specific hematopoietic progenitors in healthy controls (n 5 20) and the entire patient cohort (n 5 89) (unpaired Student t test controls). (F)
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To assess differentiation capacity of HSPCs, 1 3 103 or
6 3 103 CD341 cells were plated in duplicate in complete
semisolid methylcellulose (Methocult H4435; STEMCELL Tech-
nologies). Differentiated colonies were counted and scored based
on morphology 14 days after culture in a humid environment
at 37°C using STEMVision camera and software (STEMCELL
Technologies).
Results and discussion
The average age of all patients was 69 years (range 40 to 92 years)
with a male:female ratio of 1.8:1 (patient characteristics are listed in
supplemental Table 1). Patients were either treatment naive or
relapsed (average number of previous treatments5 2). The average
age of healthy controls was 66 (range 32 to 85 years).
We first quantified the absolute numbers of circulating HSPCs and
found similar numbers of CD341 cells to age-matched healthy
individuals (Figure 1A). Similarly, no differences were observed
between different Binet groups (Figure 1B) or treatment-naive vs
previously treated patients (Figure 1C). Subsequently, differences
in the relative frequency of HSC subpopulations were assessed by
flow cytometry using lineage markers and CD34, CD38, CD45,
CD10, CD7, CD49f, and CD90 (supplemental Table 2). Our
analyses revealed that common myeloid and myeloerythroid
progenitors (CMPs-MEPs) (CD192CD341CD381CD45RA2CD102
CD72) were more abundant in the PB of patients with CLL
(Figure 1D-E). Conversely, myelolymphoid progenitors (CD192
CD341CD382CD45RA1) were significantly decreased in
patients’ blood compared with healthy controls. The HSC pool
(CD192CD341CD382CD45RA2), defined as a pool of HSC and
multipotent progenitors, is known to contain a heterogeneous pool
of cells with different self-renewal and differentiation capacities,9-11
was also more abundant in patients’ blood. In particular, short-term
HSCs (ST-HSCs) (CD192CD341CD382CD45RA2CD902
CD49f2), multipotent cells with limited self-renewal and repopula-
tion capacity,10 and differentiation bias toward the erythroid
lineage,11,12 were found in higher frequencies in the PB of patients
with CLL (Figure 1D-E), whereas frequencies of long-term HSCs
(CD192CD341CD382CD45RA2CD901CD49f1), cells with mul-
tipotent long-term repopulation capacity,10,13 were comparable to
healthy controls. In addition, we did not observe significant
differences within the group of treatment-naive patients stratified
by Binet stage with the exception of slightly fewer total HSCs in the
Binet C group (supplemental Figure 3). Upon dividing the entire
cohort of patients based on the treatment status, we observed
similar changes between naive and previously treated patients with
CLL (Figure 1F). Notably, PB white blood cell counts did not
correlate with higher frequencies of ST-HSCs (Figure 1G). In
addition, we did not observe differences between patient samples
with Del13q, normal karyotype, or presence of TP53 (supplemental
Figure 4). Conclusively, these results suggest that CLL cells impair
bone marrow residency of ST-HSC and MEP progenitor cells,
irrespective of previous treatments. The absence of a correlation
between full blood counts and HSPCs indicates that these changes
are already present at an early disease stage.
We next investigated the differentiation properties of PB-derived
CD341 cells. CLL-derived and healthy CD341 progenitors showed
similar proliferation capacity and generated similar numbers of
differentiated colonies (Figure 2A). We also did not observe
differences in colony formation between CD341 cells isolated from
patients with different Binet groups (Figure 2B) or between
treatment-naive and previously treated patients (Figure 2C). How-
ever, further characterization of colonies identified that CD341
progenitors from patients with CLL generated a significantly higher
proportion of myeloid colonies at the expense of erythroid
colonies compared with controls (Figure 2D-E). This skewed
differentiation of CD341 cells was predominantly driven by
treatment-naive patients compared with previously treated
patients (Figure 2F). These data demonstrate that higher
frequencies of ST-HSCs and CMP-MEPs in the PB of patients
with CLL are associated with a skewed differentiation into
myeloid cells in vitro, and progenitor cells are less likely to
produce erythrocytes. Interestingly, we found that this pheno-
type was predominantly driven from CD341 cells from normal-
karyotype patients, whereas cells from patients with Del13q
showed a more balanced differentiation output, similar to
progenitors derived from healthy controls (Figure 2G).
To our knowledge, this is the first study using high-resolution flow
cytometry identifying significantly higher frequencies of PB ST-
HSCs and CMP-MEPs in patients with CLL, associated with
a skewed differentiation into myeloid colonies at the expense of
erythroid cells. These findings likely reflect first signs of bone
marrow failure and exhaustion of normal stem and progenitor cells
and complement recently published data, indicating that the bone
marrow of patients with CLL is depleted in phenotypically defined
HSC, multipotent progenitor, CMP, and common lymphoid
progenitors.14 It is therefore reasonable to assume that disease-
induced alterations in bone marrow niches contribute to the
redistribution of HSPCs, which then no longer participate in normal
blood production.
Although these conclusions are drawn from in vitro experiments and
whether skewing is also present in physiological niches in vivo
remains unknown, they are supported by clinical findings in this
patient population. Early- to intermediate-stage patients almost
never present with neutropenia, whereas mild anemia is a common
finding in this patient population. In contrast, myelosuppression is
more common in previously treated patients, and the absence of
a differentiation bias of PB CD341 cells in this group may be
a result of direct cytotoxic effects from therapies on normal HSCs.
In addition, the observation that progenitor cells from Del13q
patients behave more similarly to normal healthy control cells with
regard to their differentiation potential may reflect the better overall
Figure 1. (continued) Dot-plot showing relative abundance of specific hematopoietic progenitors in healthy controls (n 5 20) and in patients with CLL by treatment group
(ordinary 1-way ANOVA); naive patients, n 5 66; previously treated patients, n 5 23. (G) Linear regression plots showing correlation of ST-HSC frequencies (as %CD341) to
white blood cell counts in naive patients (n 5 58) (above), and previously treated patients (n 5 15) (below). P values from unpaired Student t tests or 1-way ANOVA are
denoted with asterisks according to the following: ****P , .0001, ***P , .001, **P , .01, *P , .05. GMP, granulocyte monocyte progenitors; B-NK, B-NK progenitors; WBC,
white blood cell.
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prognosis of this group compared with other cytogenetically
defined subgroups.15 Whether the skewed differentiation of PB
HSPCs in patients with CLL reflects compensation mechanisms of
normal progenitor cells in response to an abnormal cytokine and
niche environment or relates to recurrent genetic abnormalities
found in a subset of HSCs remains to be investigated. Our data
provide further insights on the mechanisms causing cytopenia in
patients with CLL and suggest that a pathologic mobilization of
ST-HSCs is a contributing factor.
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Figure 2. Functional characterization of PB CD341 progenitor cells from patients with CLL. (A-C) Bar plots showing the absolute number of colony-forming units
(CFU) generated in methylcellulose assays by PB CD341 of (A) healthy controls (n 5 17) and of patients with CLL (n 5 55) (unpaired Student t test; P , .05). Comparison
between healthy controls and Binet groups (B) or treatment-naive patients with CLL vs treated patients (C) (ordinary 1-way ANOVA followed by unpaired Student t tests).
Differentiated colonies were counted and scored based on morphology 14 days postculture in humid environment at 37°C. Colonies were analyzed using STEMVision (STEM-
CELL Technologies). (D) Representative pictures of CFUs generated by healthy or CLL-derived hematopoietic progenitors. BFU-E, burst forming unit–erythroid; CFU-GEMM,
colony-forming unit–granulocyte, erythrocyte, macrophage, megakaryocyte; CFU-GM, colony-forming unit–granulocyte, macrophage. (E-F) Dot-plots showing the composition of
CFUs generated by healthy controls and patients with CLL (E) or by naive patients with CLL or treated patients with CLL (F) (1-way ANOVA followed by unpaired Student
t test). (G) Histograms showing myeloid (left) or erythroid (right) CFU frequencies in CLL samples clustered based on chromosomal abnormalities. P values from unpaired
Student t tests or 1-way ANOVA are denoted with asterisks according to the following: ***P , .001, *P , .05.
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